Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents

dc.contributor.author	Cevik, Muge
dc.contributor.author	Orkin, Chloe
dc.date.accessioned	2020-11-18T00:38:38Z
dc.date.available	2020-11-18T00:38:38Z
dc.date.issued	2019-11-18
dc.identifier	263383043
dc.identifier	fd7e1f54-72b0-436e-a2ae-c82ce74e34bd
dc.identifier	85075210758
dc.identifier	000497012800001
dc.identifier.citation	Cevik , M & Orkin , C 2019 , ' Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents ' , Expert Opinion on Investigational Drugs , vol. Latest Articles , pp. 1-4 . https://doi.org/10.1080/13543784.2019.1692811	en
dc.identifier.issn	1354-3784
dc.identifier.other	crossref: 10.1080/13543784.2019.1692811
dc.identifier.other	ORCID: /0000-0003-1133-3874/work/65014445
dc.identifier.uri	https://hdl.handle.net/10023/21001
dc.format.extent	355734
dc.language.iso	eng
dc.relation.ispartof	Expert Opinion on Investigational Drugs	en
dc.subject	Capsid inhibitors	en
dc.subject	Capsid protein	en
dc.subject	HIV	en
dc.subject	HIV-1	en
dc.subject	Anteretrovirals	en
dc.subject	Capsid assembly	en
dc.subject	RM Therapeutics. Pharmacology	en
dc.subject	QR355 Virology	en
dc.subject	SDG 3 - Good Health and Well-being	en
dc.subject.lcc	RM	en
dc.subject.lcc	QR355	en
dc.title	Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents	en
dc.type	Journal item	en
dc.contributor.institution	University of St Andrews. School of Medicine	en
dc.identifier.doi	10.1080/13543784.2019.1692811
dc.description.status	Peer reviewed	en
dc.date.embargoedUntil	2020-11-18